RE:RE:RE:Next NRI am very much looking forward to news from the CRA (Collaborative Research Agreement) with the National Microbiology Laboratory, Public Health Agency of Canada (“PHAC”) before the end of the year.
According to the last MD&A:
"Theralase® in conjunction with UM and PHAC have modified their focus to avian influenza (H5N1).
These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® H5N1 vaccine in the ability to prevent animals from contracting H5N1, when exposed to the virus, which commenced in 2Q2024 and is expected to be completed by 4Q2024."
DJDawg wrote:
All the good discussion about the bladder study makes me want to iterate that TLT is not a one drug and one indication company.
IV Ruvidar (Rutherrin) shows great promise for solid and liquid tumours
Ruvidar has antiviral properties that are potent and only just starting to be understood
Ruvidar may have a role in vaccine development (Manitoba work ongoing)
Those multiple avenues are a nice way of de-risking things.
I look forward to good updates in the coming 1-2 months.